These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16773365)

  • 1. [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].
    Löhr JM; Faissner R; Findeisen P; Neumaier M
    Internist (Berl); 2006 Jun; 47 Suppl 1():S40-8. PubMed ID: 16773365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoproteins and glycoproteomics in pancreatic cancer.
    Pan S; Brentnall TA; Chen R
    World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
    Iovanna J; Dusetti N
    Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
    Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteome analysis in the study of lymphoma cells.
    Joubert-Caron R; Caron M
    Mass Spectrom Rev; 2005; 24(4):455-68. PubMed ID: 15389845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting targets for therapeutic validation through differential protein expression using chromatography-mass spectrometry.
    Patterson S
    Bioinformatics; 2002; 18 Suppl 2():S181. PubMed ID: 12386001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets.
    Britton D; Zen Y; Quaglia A; Selzer S; Mitra V; Löβner C; Jung S; Böhm G; Schmid P; Prefot P; Hoehle C; Koncarevic S; Gee J; Nicholson R; Ward M; Castellano L; Stebbing J; Zucht HD; Sarker D; Heaton N; Pike I
    PLoS One; 2014; 9(3):e90948. PubMed ID: 24670416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Proteomic Analysis of Differentially Expressed Protein Profiles Involved in Pancreatic Ductal Adenocarcinoma.
    Kuo KK; Kuo CJ; Chiu CY; Liang SS; Huang CH; Chi SW; Tsai KB; Chen CY; Hsi E; Cheng KH; Chiou SH
    Pancreas; 2016 Jan; 45(1):71-83. PubMed ID: 26262590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.
    Coleman O; Henry M; McVey G; Clynes M; Moriarty M; Meleady P
    Expert Rev Proteomics; 2016; 13(4):383-94. PubMed ID: 26985644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular pathology of pancreatic cancer: from bench-to-bedside translation.
    Corbo V; Tortora G; Scarpa A
    Curr Drug Targets; 2012 Jun; 13(6):744-52. PubMed ID: 22458520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer.
    Tanaka S
    Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S197-205. PubMed ID: 25749932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?
    Ansari D; Sambergs F; Johansson L; Andersson R
    Expert Rev Proteomics; 2017 Jun; 14(6):469-471. PubMed ID: 28388239
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines.
    Alhamdani MS; Youns M; Buchholz M; Gress TM; Beckers MC; Maréchal D; Bauer A; Schröder C; Hoheisel JD
    J Proteomics; 2012 Jun; 75(12):3747-59. PubMed ID: 22579748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics analysis of bodily fluids in pancreatic cancer.
    Pan S; Brentnall TA; Chen R
    Proteomics; 2015 Aug; 15(15):2705-15. PubMed ID: 25780901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma.
    Sitek B; Lüttges J; Marcus K; Klöppel G; Schmiegel W; Meyer HE; Hahn SA; Stühler K
    Proteomics; 2005 Jul; 5(10):2665-79. PubMed ID: 15924292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.